1-4 of 4
Rachel Marceau West
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Favezelimab in Combination with Pembrolizumab in Patients with Anti-PD-1-Naive Relapsed or Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1/2 Study

Nathalie A. Johnson, David Lavie, Peter Borchmann, Gareth P. Gregory, Alex F. Herrera, Leonard Minuk, Vladan Vucinic, Philippe Armand, Abraham Avigdor, Robin Gasiorowski, Yair Herishanu, Colm Keane, John Kuruvilla, Rachel Marceau West, Pallavi Pillai, Patricia Marinello, John Timmerman
Journal: Blood
Blood (2023) 142 (Supplement 1): 1693.
https://doi.org/10.1182/blood-2023-182128
Published: 2023
Journal Articles

Favezelimab (anti-LAG-3) Plus Pembrolizumab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Cohort 3 of a Multicohort Open-Label Phase 1/2 Study

Armando Santoro, Nathalie A. Johnson, Kerry J. Savage, Abraham Avigdor, Ali Bazargan, Peter Borchmann, Robin Gasiorowski, Gareth P. Gregory, Yair Herishanu, Sumit Madan, Leonard Minuk, Gerardo Musuraca, Rachel Marceau West, Pallavi Pillai, Patricia Marinello, Pier Luigi Zinzani
Journal: Blood
Blood (2023) 142 (Supplement 1): 1725.
https://doi.org/10.1182/blood-2023-182536
Published: 2023
Journal Articles

Favezelimab in Combination with Pembrolizumab in Patients with Heavily Pretreated Anti-PD-1-Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1/2 Study

John Timmerman, David Lavie, Nathalie A. Johnson, Abraham Avigdor, Peter Borchmann, Charalambos Andreadis, Ali Bazargan, Gareth P. Gregory, Colm Keane, Inna Tzoran, Vladan Vucinic, Pier Luigi Zinzani, Rachel Marceau West, Pallavi Pillai, Patricia Marinello, Alex F. Herrera
Journal: Blood
Blood (2023) 142 (Supplement 1): 4440.
https://doi.org/10.1182/blood-2023-182019
Published: 2023
Journal Articles

Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma after Anti-PD-1 Treatment

John Timmerman, David Lavie, Nathalie A. Johnson, Abraham Avigdor, Peter Borchmann, Charalambos Andreadis, Ali Bazargan, Gareth P. Gregory, Colm Keane, Inna Tsoran-Rosenthal, Vladan Vucinic, Pier Luigi Zinzani, Rachel Marceau West, Pallavi Pillai, Akash Nahar, Alex F. Herrera
Journal: Blood
Blood (2022) 140 (Supplement 1): 768–770.
https://doi.org/10.1182/blood-2022-166670
Published: 2022